Cargando…

Successful outcomes using Long Acting Buprenorphine (LAB - Buvidal) to treat Codeine, Tramadol and other Opioid Analgesia Dependencies (OAD) in Wales during the Pandemic

INTRODUCTION: Long Acting Buprenorphine (LAB) – Buvidal (CAM2038) – is a prolonged release treatment for opioid dependence in adults. Its extensive use was funded by Welsh Government during the pandemic in Wales and it has been found to be a significantly better than oral medications in improving qu...

Descripción completa

Detalles Bibliográficos
Autores principales: Melichar, J., Graver, F., Parimelalagan, L., Lewis, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563216/
http://dx.doi.org/10.1192/j.eurpsy.2022.855
_version_ 1784808347940159488
author Melichar, J.
Graver, F.
Parimelalagan, L.
Lewis, J.
author_facet Melichar, J.
Graver, F.
Parimelalagan, L.
Lewis, J.
author_sort Melichar, J.
collection PubMed
description INTRODUCTION: Long Acting Buprenorphine (LAB) – Buvidal (CAM2038) – is a prolonged release treatment for opioid dependence in adults. Its extensive use was funded by Welsh Government during the pandemic in Wales and it has been found to be a significantly better than oral medications in improving quality of life, possibly through providing allostatic craving and anxiety reduction OBJECTIVES: This is a case series of 10 patients who were referred to Community Addiction Services in North and South West Wales with OAD. METHODS: Patients were mainly using Codeine or Tramadol and were referred due to either ongoing illicit use or via primary care services requesting support. As part of the pandemic initiative, they were initiated on Buvidal and followed up. RESULTS: All ten patients successfully started on Buvidal without significant issues. As a group, if transferred straight to Buvidal, they tended to have fewer significant withdrawal symptoms prior to starting on the Buvidal compared to those on Methadone or Heroin. They were treated on the usual range of Buvidal doses (1 on 64mg, the others on 96-128mg monthly). They have all stabilised and successfully moved on with their lives on Buvidal. One has used the time on Buvidal to have psychological input around past traumas and successfully detoxified in the community using Buvidal. CONCLUSIONS: Recommendations for services considering OAD - it is a surprisingly effective treatment which is easy to start. It has the scope for being both an effective OAD recovery medication and a potentially simple detoxification strategy for this patient group. DISCLOSURE: Professor Melichar has provided consultancy work, presentations, training and chaired panel discussions for all the companies in this area in the UK and some outside the UK. Recent work includes Althea (UK), Britannia (UK), Camurus (UK and Global), Martin
format Online
Article
Text
id pubmed-9563216
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95632162022-10-17 Successful outcomes using Long Acting Buprenorphine (LAB - Buvidal) to treat Codeine, Tramadol and other Opioid Analgesia Dependencies (OAD) in Wales during the Pandemic Melichar, J. Graver, F. Parimelalagan, L. Lewis, J. Eur Psychiatry Abstract INTRODUCTION: Long Acting Buprenorphine (LAB) – Buvidal (CAM2038) – is a prolonged release treatment for opioid dependence in adults. Its extensive use was funded by Welsh Government during the pandemic in Wales and it has been found to be a significantly better than oral medications in improving quality of life, possibly through providing allostatic craving and anxiety reduction OBJECTIVES: This is a case series of 10 patients who were referred to Community Addiction Services in North and South West Wales with OAD. METHODS: Patients were mainly using Codeine or Tramadol and were referred due to either ongoing illicit use or via primary care services requesting support. As part of the pandemic initiative, they were initiated on Buvidal and followed up. RESULTS: All ten patients successfully started on Buvidal without significant issues. As a group, if transferred straight to Buvidal, they tended to have fewer significant withdrawal symptoms prior to starting on the Buvidal compared to those on Methadone or Heroin. They were treated on the usual range of Buvidal doses (1 on 64mg, the others on 96-128mg monthly). They have all stabilised and successfully moved on with their lives on Buvidal. One has used the time on Buvidal to have psychological input around past traumas and successfully detoxified in the community using Buvidal. CONCLUSIONS: Recommendations for services considering OAD - it is a surprisingly effective treatment which is easy to start. It has the scope for being both an effective OAD recovery medication and a potentially simple detoxification strategy for this patient group. DISCLOSURE: Professor Melichar has provided consultancy work, presentations, training and chaired panel discussions for all the companies in this area in the UK and some outside the UK. Recent work includes Althea (UK), Britannia (UK), Camurus (UK and Global), Martin Cambridge University Press 2022-09-01 /pmc/articles/PMC9563216/ http://dx.doi.org/10.1192/j.eurpsy.2022.855 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Melichar, J.
Graver, F.
Parimelalagan, L.
Lewis, J.
Successful outcomes using Long Acting Buprenorphine (LAB - Buvidal) to treat Codeine, Tramadol and other Opioid Analgesia Dependencies (OAD) in Wales during the Pandemic
title Successful outcomes using Long Acting Buprenorphine (LAB - Buvidal) to treat Codeine, Tramadol and other Opioid Analgesia Dependencies (OAD) in Wales during the Pandemic
title_full Successful outcomes using Long Acting Buprenorphine (LAB - Buvidal) to treat Codeine, Tramadol and other Opioid Analgesia Dependencies (OAD) in Wales during the Pandemic
title_fullStr Successful outcomes using Long Acting Buprenorphine (LAB - Buvidal) to treat Codeine, Tramadol and other Opioid Analgesia Dependencies (OAD) in Wales during the Pandemic
title_full_unstemmed Successful outcomes using Long Acting Buprenorphine (LAB - Buvidal) to treat Codeine, Tramadol and other Opioid Analgesia Dependencies (OAD) in Wales during the Pandemic
title_short Successful outcomes using Long Acting Buprenorphine (LAB - Buvidal) to treat Codeine, Tramadol and other Opioid Analgesia Dependencies (OAD) in Wales during the Pandemic
title_sort successful outcomes using long acting buprenorphine (lab - buvidal) to treat codeine, tramadol and other opioid analgesia dependencies (oad) in wales during the pandemic
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563216/
http://dx.doi.org/10.1192/j.eurpsy.2022.855
work_keys_str_mv AT melicharj successfuloutcomesusinglongactingbuprenorphinelabbuvidaltotreatcodeinetramadolandotheropioidanalgesiadependenciesoadinwalesduringthepandemic
AT graverf successfuloutcomesusinglongactingbuprenorphinelabbuvidaltotreatcodeinetramadolandotheropioidanalgesiadependenciesoadinwalesduringthepandemic
AT parimelalaganl successfuloutcomesusinglongactingbuprenorphinelabbuvidaltotreatcodeinetramadolandotheropioidanalgesiadependenciesoadinwalesduringthepandemic
AT lewisj successfuloutcomesusinglongactingbuprenorphinelabbuvidaltotreatcodeinetramadolandotheropioidanalgesiadependenciesoadinwalesduringthepandemic